Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Newnorm in Primary Immunodeficiency Diseases
NCT04640142Phase 3Active, not recruiting
- Sponsor
- Octapharma
- Start
- Aug 2021
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 7
01
Overview
A Phase 3 trial of Newnorm in primary immunodeficiency disease (PID), sponsored by Octapharma. Started Aug 2021; status: active, not recruiting.
02
Drugs
Newnorm
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT04640142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640142.